

# News Release

## News Release

CONTACT: Andrew Bright  
+ 1 (484) 530 3922  
[andrew.bright@oncura.com](mailto:andrew.bright@oncura.com)  
[www.oncura.com](http://www.oncura.com)

### **ONCURA™ Successfully Completes SeedNet™ Installation at Columbia Presbyterian with Dr. Katz Using the New 17 gauge IceRod™ Technology.**

Philadelphia, PA (Sept 23, 2004) — ONCURA, a global leader in minimally invasive prostate cancer treatment is pleased to announce that Dr. Aaron Katz (Associate Professor of Clinical Urology, Columbia University Medical Center, New York), a pioneer in the clinical use of cryotherapy, will adopt their 17 gauge IceRods. The recently launched IceRod increases the utility of ONCURA's patented 17 gauge cryoneedle technology, allowing physicians to utilize a minimally invasive option that offers a larger therapeutic ice ball.

"With the introduction of ONCURA's minimally invasive 17 gauge IceRod needles I hope to improve on the excellent clinical results I've previously demonstrated," said Dr Katz. He added, "The introduction of the IceRod with its larger therapeutic ice ball allows me to conveniently and effectively treat prostate cancer, while minimizing the morbidities of this treatment option."

The IceRod introduction is a logical development of ONCURA's approach to treating prostate cancer; effective treatment with minimal impact on the patient. ONCURA's patented 17 gauge technology reduces the invasiveness of cryotherapy when compared to older and larger cryoprobe technologies, and the ability of the IceRod needles to treat a larger volume may reduce procedure time.

"The size of the ice ball generated by the 17 gauge IceRod is exactly what I require to maintain the clinical approach I have in treating prostate cancer," said Dr Katz. He added, "The minimally invasive approach of ONCURA's 17 gauge needles, coupled with the IceRod's ability to treat prostates up to 60gm was instrumental in my decision to adopt their technology."

Dr. Katz has spoken at numerous meetings, conferences and symposia in the U.S. and abroad and is widely published, in the Journal of Urology, Contemporary Urology, Molecular Urology, British Journal of Urology, Cancer, and Cancer Research.

Dr. Katz is a member of the American Urological Association, the Society of Urologic Cryosurgeons, the Society of University Urologists and the Southwest Oncology Group. Over the course of his career, Dr. Katz has won numerous awards and grants, including one from the NIH to study the molecular staging of prostate cancer, as well as one from CaPCure for the investigation of an antibody to prevent the recurrence of prostate cancer.

ONCURA was created through the merger of Amersham plc's brachytherapy business and Galil Medical Ltd.'s urology business. Galil is a division of Elron (ELRN). Headquartered in the United States, ONCURA operates as an independent business, with a major presence in the treatment of prostate cancer. On April 8, 2004, General Electric (GE) completed its previously announced acquisition of Amersham.